Rationale and design of RESILIENCE: A prospective randomized clinical trial evaluating remote ischaemic conditioning for the prevention of anthracycline cardiotoxicity
Anthracyclines, alone or in combination, remain the first-line therapy for many cancers, including various forms of lymphoma, breast cancer, leukaemia, melanoma, and uterine and gastric cancers. Every year, anthracyclines are administered to >3 million European citizens to treat a first cancer. The curative potential of anthracycline therapy is determined by